Denali Therapeutics Inc (NASDAQ:DNLI) COO Alexander O. Schuth sold 7,500 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $18.16, for a total value of $136,200.00.
Shares of DNLI stock traded down $0.70 during trading hours on Thursday, reaching $18.94. 5,034 shares of the company’s stock were exchanged, compared to its average volume of 350,351. The company has a market cap of $1.68 billion, a P/E ratio of -48.00 and a beta of 2.20. The company’s 50 day moving average is $18.87 and its two-hundred day moving average is $21.25. Denali Therapeutics Inc has a 1 year low of $13.78 and a 1 year high of $28.86. The company has a debt-to-equity ratio of 0.15, a current ratio of 10.65 and a quick ratio of 10.66.
Denali Therapeutics (NASDAQ:DNLI) last issued its earnings results on Tuesday, August 6th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.15). The business had revenue of $4.20 million for the quarter, compared to analysts’ expectations of $4.52 million. Denali Therapeutics had a negative return on equity of 11.03% and a negative net margin of 40.78%. As a group, analysts predict that Denali Therapeutics Inc will post -2.02 EPS for the current fiscal year.
Several analysts have commented on the company. TheStreet downgraded Denali Therapeutics from a “c-” rating to a “d” rating in a research note on Thursday, June 13th. ValuEngine raised Denali Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, September 4th. Zacks Investment Research downgraded Denali Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, August 7th. BTIG Research assumed coverage on Denali Therapeutics in a research note on Friday, August 9th. They set a “buy” rating and a $30.00 price objective for the company. Finally, Morgan Stanley set a $32.00 price objective on Denali Therapeutics and gave the company a “buy” rating in a research note on Friday, August 9th. Two equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $27.33.
Denali Therapeutics Company Profile
Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease.
Recommended Story: Stock Symbols Definition, Examples, Lookup
Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.